NASD · Healthcare · Medical Care Facilities · USA
Starling Oncology Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Care Facilities industry.
Starling Oncology Inc provides cancer care services across multiple markets in several states through physician-owned clinics and contracted providers. The company operates medical oncology and radiation oncology services on both fee-for-service and value-based contract bases, managing patients under risk-sharing arrangements with payers. Additionally, the company offers specialty pharmacy services and clinical trial management.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Starling Oncology Inc stock.
Undervalued: intrinsic value $7.16 per share, market price $3.40, margin of safety 52.5% (as of 2026-11-17).
A 1.2x revenue multiple, discounted for its losses, values the shares at $7.16; the price of $3.40 is 53% below that value.
17 more funds hold it; the full list is part of the paid plan.
All 48 Medical Care Facilities stocks
STLN is undervalued (as of the 2026-11-17 close). A 1.2x revenue multiple, discounted for its losses, values the shares at $7.16; the price of $3.40 is 53% below that value.
$7.16 per share (as of the 2026-11-17 close), against a market price of $3.40. That is a margin of safety of 52.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.